Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
JW (Cayman) Therapeutics Co. Ltd. (HK:2126)
HKEX:2126
Holding HK:2126?
Track your performance easily
2126 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$1.19 - HK$2.68
Previous CloseHK$1.28
Volume391.50K
Average Volume (3M)1.15M
Market Cap
HK$531.77M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Mar 19, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.67
Shares OutstandingN/A
10 Day Avg. Volume561,500
30 Day Avg. Volume1,150,440
Standard Deviation0.21
R-Squared0.42
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)13.58
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
JW (Cayman) Therapeutics Co. Ltd. News
PremiumCompany Announcements
JW Cayman Therapeutics Appoints Deloitte as New Auditor
PremiumCompany Announcements
JW Therapeutics Announces New Share Grants
PremiumCompany Announcements
JW Therapeutics Announces Board Structure
PremiumCompany Announcements
JW Therapeutics Announces Board Appointment
PremiumCompany Announcements
JW Therapeutics Reports Steady Performance and Cost Savings
PremiumCompany Announcements
JW Therapeutics’ Carteyva® Wins Key Approval
PremiumCompany Announcements
JW Therapeutics Prepares for Key Board MeetingPremiumCompany Announcements
JW Therapeutics Announces Board StructureOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.05% Mutual Funds
― Other Institutional Investors
99.95% Public Companies and
Individual Investors
2126 FAQ
What was JW (Cayman) Therapeutics Co. Ltd.’s price range in the past 12 months?
JW (Cayman) Therapeutics Co. Ltd. lowest stock price was HK$1.19 and its highest was HK$2.68 in the past 12 months.
What is JW (Cayman) Therapeutics Co. Ltd.’s market cap?
Currently, no data Available
When is JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date?
JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date is Mar 19, 2025 which is in 86 days.
How were JW (Cayman) Therapeutics Co. Ltd.’s earnings last quarter?
JW (Cayman) Therapeutics Co. Ltd. released its earnings results on Aug 28, 2024. The company reported -HK$0.619 earnings per share for the quarter, beating the consensus estimate of -HK$0.683 by HK$0.064.
Is JW (Cayman) Therapeutics Co. Ltd. overvalued?
According to Wall Street analysts JW (Cayman) Therapeutics Co. Ltd.’s price is currently Overvalued.
Does JW (Cayman) Therapeutics Co. Ltd. pay dividends?
JW (Cayman) Therapeutics Co. Ltd. does not currently pay dividends.
What is JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate?
JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JW (Cayman) Therapeutics Co. Ltd. have?
JW (Cayman) Therapeutics Co. Ltd. has 415,446,260 shares outstanding.
What happened to JW (Cayman) Therapeutics Co. Ltd.’s price movement after its last earnings report?
JW (Cayman) Therapeutics Co. Ltd. reported an EPS of -HK$0.619 in its last earnings report, beating expectations of -HK$0.683. Following the earnings report the stock price went up 1.527%.
Which hedge fund is a major shareholder of JW (Cayman) Therapeutics Co. Ltd.?
Currently, no hedge funds are holding shares in HK:2126
---
JW (Cayman) Therapeutics Co. Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.76%
12-Months-Change
Fundamentals
Return on Equity
-34.81%
Trailing 12-Months
Asset Growth
-25.66%
Trailing 12-Months
Company Description
JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
---
Technical Analysis
Viva Biotech Holdings
―
Newlink Technology Inc.
―
RemeGen Co. Ltd. Class H
―
Zhenro Services Group Limited
―
---